Poly(lactic acid-glycolic acid) nanoparticles markedly improve immunological protection provided by peptide P10 against murine paracoccidioidomycosis

Detalhes bibliográficos
Autor(a) principal: Amaral, Andre C.
Data de Publicação: 2010
Outros Autores: Marques, Alexandre F., Munoz, Julian E., Bocca, Anamelia L., Simioni, Andreza R., Tedesco, Antonio C., Morais, Paulo C., Travassos, Luiz Rodolpho [UNIFESP], Taborda, Carlos Pelleschi [UNIFESP], Felipe, Maria Sueli S.
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da UNIFESP
Texto Completo: http://dx.doi.org/10.1111/j.1476-5381.2009.00617.x
http://repositorio.unifesp.br/handle/11600/32293
Resumo: Background and purpose:The present study reports on the preparation and testing of a sustained delivery system for the immunomodulatory peptide P10 aimed at reducing the in vivo degradation of the peptide and the amount required to elicit a protective immune response against paracoccidioidomycosis.Experimental approach:BALB/c mice were infected with the yeast Paracoccidioides brasiliensis to mimic the chronic form of paracoccidioidomycosis. the animals were treated daily with sulfamethoxazole/trimethoprim alone or combined with peptide P10, either emulsified in Freund's adjuvant or entrapped in poly(lactic acid-glycolic acid) (PLGA) nanoparticles at different concentrations (1 mu g, 5 mu g, 10 mu g, 20 mu g or 40 mu g center dot 50 mu L-1). Therapeutic efficacy was assessed as fungal burden in tissues and the immune response by quantitative determination of cytokines.Key results:Animals given combined chemotherapy and P10 nanotherapy presented a marked reduction of fungal load in the lungs, compared with the non-treated animals. After 30 days of treatment, P10 entrapped within PLGA (1 mu g center dot 50 mu L-1) was more effective than 'free' P10 emulsified in Freund's adjuvant (20 mu g center dot 50 mu L-1), as an adjuvant to chemotherapy. After treatment for 90 days, the higher doses of P10 entrapped within PLGA (5 or 10 mu g center dot 50 mu L-1) were most effective. Treatment with P10 emulsified in Freund's adjuvant (20 mu g center dot 50 mu L-1) or P10 entrapped within PLGA (1 mu g center dot 50 mu L-1) were accompanied by high levels of interferon-gamma in lung.Conclusions and implications:Combination of sulfamethoxazole/trimethoprim with the P10 peptide entrapped within PLGA demonstrated increased therapeutic efficacy against paracoccidioidomycosis. P10 incorporation into PLGA nanoparticles dramatically reduced the peptide amount necessary to elicit a protective effect.
id UFSP_4690bb2731a20ff95913d815650e6737
oai_identifier_str oai:repositorio.unifesp.br/:11600/32293
network_acronym_str UFSP
network_name_str Repositório Institucional da UNIFESP
repository_id_str 3465
spelling Poly(lactic acid-glycolic acid) nanoparticles markedly improve immunological protection provided by peptide P10 against murine paracoccidioidomycosisimmunomodulatory peptideantifungal therapybiodegradable polymersdrug deliverynanobiotechnologyBackground and purpose:The present study reports on the preparation and testing of a sustained delivery system for the immunomodulatory peptide P10 aimed at reducing the in vivo degradation of the peptide and the amount required to elicit a protective immune response against paracoccidioidomycosis.Experimental approach:BALB/c mice were infected with the yeast Paracoccidioides brasiliensis to mimic the chronic form of paracoccidioidomycosis. the animals were treated daily with sulfamethoxazole/trimethoprim alone or combined with peptide P10, either emulsified in Freund's adjuvant or entrapped in poly(lactic acid-glycolic acid) (PLGA) nanoparticles at different concentrations (1 mu g, 5 mu g, 10 mu g, 20 mu g or 40 mu g center dot 50 mu L-1). Therapeutic efficacy was assessed as fungal burden in tissues and the immune response by quantitative determination of cytokines.Key results:Animals given combined chemotherapy and P10 nanotherapy presented a marked reduction of fungal load in the lungs, compared with the non-treated animals. After 30 days of treatment, P10 entrapped within PLGA (1 mu g center dot 50 mu L-1) was more effective than 'free' P10 emulsified in Freund's adjuvant (20 mu g center dot 50 mu L-1), as an adjuvant to chemotherapy. After treatment for 90 days, the higher doses of P10 entrapped within PLGA (5 or 10 mu g center dot 50 mu L-1) were most effective. Treatment with P10 emulsified in Freund's adjuvant (20 mu g center dot 50 mu L-1) or P10 entrapped within PLGA (1 mu g center dot 50 mu L-1) were accompanied by high levels of interferon-gamma in lung.Conclusions and implications:Combination of sulfamethoxazole/trimethoprim with the P10 peptide entrapped within PLGA demonstrated increased therapeutic efficacy against paracoccidioidomycosis. P10 incorporation into PLGA nanoparticles dramatically reduced the peptide amount necessary to elicit a protective effect.Univ Brasilia, Dept Biol Celular, Mol Biol Lab, Inst Biol Sci, BR-70910900 Brasilia, DF, BrazilUniv Brasilia, Inst Phys, BR-70910900 Brasilia, DF, BrazilUniv Catolica Brasilia, Brasilia, DF, BrazilUniv São Paulo, Inst Chem, BR-14049 Ribeirao Preto, BrazilUniv São Paulo, Inst Biomed Sci, São Paulo, BrazilUniv São Paulo, Med Mycol Lab, LIM53, MTSP, São Paulo, BrazilUniversidade Federal de São Paulo, Dept Microbiol Immunol & Parasitol, São Paulo, BrazilUniversidade Federal de São Paulo, Dept Microbiol Immunol & Parasitol, São Paulo, BrazilWeb of ScienceConselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)Wiley-BlackwellUniversidade de Brasília (UnB)Univ Catolica BrasiliaUniversidade de São Paulo (USP)Universidade Federal de São Paulo (UNIFESP)Amaral, Andre C.Marques, Alexandre F.Munoz, Julian E.Bocca, Anamelia L.Simioni, Andreza R.Tedesco, Antonio C.Morais, Paulo C.Travassos, Luiz Rodolpho [UNIFESP]Taborda, Carlos Pelleschi [UNIFESP]Felipe, Maria Sueli S.2016-01-24T13:59:21Z2016-01-24T13:59:21Z2010-03-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersion1126-1132http://dx.doi.org/10.1111/j.1476-5381.2009.00617.xBritish Journal of Pharmacology. Malden: Wiley-Blackwell Publishing, Inc, v. 159, n. 5, p. 1126-1132, 2010.10.1111/j.1476-5381.2009.00617.x0007-1188http://repositorio.unifesp.br/handle/11600/32293WOS:000275402000014engBritish Journal of Pharmacologyinfo:eu-repo/semantics/openAccesshttp://olabout.wiley.com/WileyCDA/Section/id-406071.htmlreponame:Repositório Institucional da UNIFESPinstname:Universidade Federal de São Paulo (UNIFESP)instacron:UNIFESP2022-11-04T15:08:28Zoai:repositorio.unifesp.br/:11600/32293Repositório InstitucionalPUBhttp://www.repositorio.unifesp.br/oai/requestbiblioteca.csp@unifesp.bropendoar:34652022-11-04T15:08:28Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)false
dc.title.none.fl_str_mv Poly(lactic acid-glycolic acid) nanoparticles markedly improve immunological protection provided by peptide P10 against murine paracoccidioidomycosis
title Poly(lactic acid-glycolic acid) nanoparticles markedly improve immunological protection provided by peptide P10 against murine paracoccidioidomycosis
spellingShingle Poly(lactic acid-glycolic acid) nanoparticles markedly improve immunological protection provided by peptide P10 against murine paracoccidioidomycosis
Amaral, Andre C.
immunomodulatory peptide
antifungal therapy
biodegradable polymers
drug delivery
nanobiotechnology
title_short Poly(lactic acid-glycolic acid) nanoparticles markedly improve immunological protection provided by peptide P10 against murine paracoccidioidomycosis
title_full Poly(lactic acid-glycolic acid) nanoparticles markedly improve immunological protection provided by peptide P10 against murine paracoccidioidomycosis
title_fullStr Poly(lactic acid-glycolic acid) nanoparticles markedly improve immunological protection provided by peptide P10 against murine paracoccidioidomycosis
title_full_unstemmed Poly(lactic acid-glycolic acid) nanoparticles markedly improve immunological protection provided by peptide P10 against murine paracoccidioidomycosis
title_sort Poly(lactic acid-glycolic acid) nanoparticles markedly improve immunological protection provided by peptide P10 against murine paracoccidioidomycosis
author Amaral, Andre C.
author_facet Amaral, Andre C.
Marques, Alexandre F.
Munoz, Julian E.
Bocca, Anamelia L.
Simioni, Andreza R.
Tedesco, Antonio C.
Morais, Paulo C.
Travassos, Luiz Rodolpho [UNIFESP]
Taborda, Carlos Pelleschi [UNIFESP]
Felipe, Maria Sueli S.
author_role author
author2 Marques, Alexandre F.
Munoz, Julian E.
Bocca, Anamelia L.
Simioni, Andreza R.
Tedesco, Antonio C.
Morais, Paulo C.
Travassos, Luiz Rodolpho [UNIFESP]
Taborda, Carlos Pelleschi [UNIFESP]
Felipe, Maria Sueli S.
author2_role author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Universidade de Brasília (UnB)
Univ Catolica Brasilia
Universidade de São Paulo (USP)
Universidade Federal de São Paulo (UNIFESP)
dc.contributor.author.fl_str_mv Amaral, Andre C.
Marques, Alexandre F.
Munoz, Julian E.
Bocca, Anamelia L.
Simioni, Andreza R.
Tedesco, Antonio C.
Morais, Paulo C.
Travassos, Luiz Rodolpho [UNIFESP]
Taborda, Carlos Pelleschi [UNIFESP]
Felipe, Maria Sueli S.
dc.subject.por.fl_str_mv immunomodulatory peptide
antifungal therapy
biodegradable polymers
drug delivery
nanobiotechnology
topic immunomodulatory peptide
antifungal therapy
biodegradable polymers
drug delivery
nanobiotechnology
description Background and purpose:The present study reports on the preparation and testing of a sustained delivery system for the immunomodulatory peptide P10 aimed at reducing the in vivo degradation of the peptide and the amount required to elicit a protective immune response against paracoccidioidomycosis.Experimental approach:BALB/c mice were infected with the yeast Paracoccidioides brasiliensis to mimic the chronic form of paracoccidioidomycosis. the animals were treated daily with sulfamethoxazole/trimethoprim alone or combined with peptide P10, either emulsified in Freund's adjuvant or entrapped in poly(lactic acid-glycolic acid) (PLGA) nanoparticles at different concentrations (1 mu g, 5 mu g, 10 mu g, 20 mu g or 40 mu g center dot 50 mu L-1). Therapeutic efficacy was assessed as fungal burden in tissues and the immune response by quantitative determination of cytokines.Key results:Animals given combined chemotherapy and P10 nanotherapy presented a marked reduction of fungal load in the lungs, compared with the non-treated animals. After 30 days of treatment, P10 entrapped within PLGA (1 mu g center dot 50 mu L-1) was more effective than 'free' P10 emulsified in Freund's adjuvant (20 mu g center dot 50 mu L-1), as an adjuvant to chemotherapy. After treatment for 90 days, the higher doses of P10 entrapped within PLGA (5 or 10 mu g center dot 50 mu L-1) were most effective. Treatment with P10 emulsified in Freund's adjuvant (20 mu g center dot 50 mu L-1) or P10 entrapped within PLGA (1 mu g center dot 50 mu L-1) were accompanied by high levels of interferon-gamma in lung.Conclusions and implications:Combination of sulfamethoxazole/trimethoprim with the P10 peptide entrapped within PLGA demonstrated increased therapeutic efficacy against paracoccidioidomycosis. P10 incorporation into PLGA nanoparticles dramatically reduced the peptide amount necessary to elicit a protective effect.
publishDate 2010
dc.date.none.fl_str_mv 2010-03-01
2016-01-24T13:59:21Z
2016-01-24T13:59:21Z
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://dx.doi.org/10.1111/j.1476-5381.2009.00617.x
British Journal of Pharmacology. Malden: Wiley-Blackwell Publishing, Inc, v. 159, n. 5, p. 1126-1132, 2010.
10.1111/j.1476-5381.2009.00617.x
0007-1188
http://repositorio.unifesp.br/handle/11600/32293
WOS:000275402000014
url http://dx.doi.org/10.1111/j.1476-5381.2009.00617.x
http://repositorio.unifesp.br/handle/11600/32293
identifier_str_mv British Journal of Pharmacology. Malden: Wiley-Blackwell Publishing, Inc, v. 159, n. 5, p. 1126-1132, 2010.
10.1111/j.1476-5381.2009.00617.x
0007-1188
WOS:000275402000014
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv British Journal of Pharmacology
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
http://olabout.wiley.com/WileyCDA/Section/id-406071.html
eu_rights_str_mv openAccess
rights_invalid_str_mv http://olabout.wiley.com/WileyCDA/Section/id-406071.html
dc.format.none.fl_str_mv 1126-1132
dc.publisher.none.fl_str_mv Wiley-Blackwell
publisher.none.fl_str_mv Wiley-Blackwell
dc.source.none.fl_str_mv reponame:Repositório Institucional da UNIFESP
instname:Universidade Federal de São Paulo (UNIFESP)
instacron:UNIFESP
instname_str Universidade Federal de São Paulo (UNIFESP)
instacron_str UNIFESP
institution UNIFESP
reponame_str Repositório Institucional da UNIFESP
collection Repositório Institucional da UNIFESP
repository.name.fl_str_mv Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)
repository.mail.fl_str_mv biblioteca.csp@unifesp.br
_version_ 1814268320521650176